Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GW Pharmaceuticals Reports Strong Phase 3 Data for Cannabis Drug

By Ryan Bushey | May 25, 2017

British-based GW Pharmaceuticals received more good news regarding its cannabis-based drug Epidiolex.

The drug maker announced positive Phase 3 data from a randomized study testing the treatment, which is a liquid formulation of purified, plant-derived cannabidiol (CBD). Researchers randomized120 treatment-resistant children ages two to 18 years diagnosed with a rare, severe form of epilepsy called Dravet syndrome.

Investigators gave patients either 20 mg per kilogram of body weight per day of GW’s treatment or placebo in addition to standard therapies for this condition over a 14-week period. Study participants had previously tried a median of four anti-epileptic drugs and were taking a median of three of them during the study.

Results indicated that Epidiolex significantly reduced the frequency of monthly convulsive seizure frequency better than placebo in those children receiving the drug along with standard treatment. 

The experimental treatment caused a 39 percent median reduction in convulsive seizures versus 13 percent in the placebo group.

Overall, the drug was able to improve patients’ conditions and helped more individuals become seizure-free than placebo.

“Dravet syndrome is one of the most difficult types of epilepsy to treat and many of the children in this study were experiencing dozens, even hundreds, of seizures per month despite taking multiple concurrent anti-epileptic medications,” said lead study author Dr. Orrin Devinsky, M.D., of NYU Langone Medical Center’s Comprehensive Epilepsy Center. These results suggest that Epidiolex can provide clinically meaningful benefits and I look forward to the prospect of an appropriately standardized and tested pharmaceutical formulation of cannabidiol available as a treatment option for these patients.”

These study results, published in The New England Journal of Medicine, are the only well-controlled clinical evaluation of a cannabinoid medication for this type of condition.

Epidiolex has previously received a fast track designation from the U.S. Food and Drug Administration (FDA) for Dravet Syndrome and an Orphan Designation from the European Medicines Agency for Dravet and another condition called Lennox-Gastaut Syndrome.

The company is still on track to submit a new drug application to the FDA by the middle of this year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE